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Abstract. Medicine sellers are widely used for fever and malaria treatment in sub-Saharan Africa, but concerns
surround the appropriateness of drugs and information provided. Because there is increasing interest in improving their
services, we reviewed the literature on their characteristics and interventions to improve their malaria-related practices.
Sixteen interventions were identified, involving a mixture of training/capacity building, demand generation, quality
assurance, and creating an enabling environment. Although evidence is insufficient to prove which approaches are
superior, tentative conclusions were possible. Interventions increased rates of appropriate treatment, and medicine
sellers were willing to participate. Features of successful interventions included a comprehensive situation analysis of the
legal and market environment; buy-in from medicine sellers, community members and government; use of a combination
of approaches; and maintenance of training and supervision. Interventions must be adapted to include artemisinin-based
combination therapies, and their sustainability and potential to operate at a national level should be further explored.
INTRODUCTION
An extensive literature on treatment seeking for malaria
and fever in sub-Saharan Africa demonstrates that medicine
sellers are a widely used source of drugs for fever and malaria.
The proportion of caregivers visiting shops during recent
childhood illness ranged from 15% to 83%, with a median
across studies of approximately 50%.1–9 For example, on the
Kenyan coast, shop-bought medicines were used first, or
solely, in 69% of childhood fevers treated.10 In Togo, only
20% of children less than five years of age with fever were
seen at a health center, and 83% were treated at home with an
antimalarial drug obtained from a street or market vendor.1
Use of medicine sellers is common in both rural and urban
areas, among children and adults, and across socioeconomic
groups.2,10–16 Medicine sellers are used even when supposedly
more convenient and cheaper alternatives exist, such as vil-
lage health workers (VHWs).16,17
Medicine sellers can be found in drug shops, general stores,
kiosks, and market stalls, and also operate as itinerant hawk-
ers, with considerable variation in retailer type across settings.
Like any business, they maintain their existence in response
to consumer demand, in this case for accessible, convenient,
reliable, and affordable antimalarial and painkiller supplies.
Medicine sellers are generally closer to homes than formal
facilities.6,18,19 For example, in coastal Kenya, 87% of rural
households live within 1 km of a shop, but only 32% live
within 2 km of a government dispensary or private clinic.10
Moreover, their service is faster, and their weekly opening
hours may be twice as long as those in health facilities.20
Because drug stock-outs are common in public facilities,
medicine sellers form an important alternative supply, and
their staff are often perceived as more friendly and approach-
able.21 Finally, cost is an important motivation.21 In some
settings, patients pay less at medicine sellers than at formal
facilities,22,23 reflecting the lack of fees for consultation or
diagnostic tests, illicit charges at some facilities, and the fact
that sub-optimal drug doses can be purchased.19 Credit may
also be more easily obtained at retail outlets.24 Even where
inexpensive or free drugs are available at facilities, people
may patronize medicine sellers to avoid the travel and time
costs involved in accessing formal care.21
However, concerns surround the appropriateness of drugs
and information that medicine sellers provide. Often the type
or dose of medicine is inappropriate for the complaint.25,26 In
a baseline survey in Kenya, only 4% of children given store-
bought chloroquine received an appropriate dose and only
2% received this dose over the recommended three-day pe-
riod. Aspirin was widely used, although it is not recom-
mended for children, with 22% receiving potentially toxic
doses.27 Polypharmacy may also be widespread, where pro-
viders prescribe additional unnecessary drugs such as antibi-
otics.26,28,29 Moreover, drugs may be of sub-standard quality
because of poor manufacture and storage.15,18,30 Finally, in
the new era of artemisinin-based combination therapy
(ACT), there is concern that medicine sellers may continue to
sell artemisinin derivatives alone (monotherapies), poten-
tially jeopardizing ACT efficacy in the long-term.31
The literature on malaria-related treatment seeking from
medicine sellers has been well reviewed and summa-
rized,12,21,32 but to date there has been no corresponding re-
view of their characteristics and operations, despite increasing
interest and experience in interventions to improve the care
received. The World Health Organization now advocates
strategies to improve home-based management of malaria,
with retailer interventions seen as one possible channel,33,34
and international meetings addressing the topic have been
held recently in Ghana and Uganda.35,36 Timely and appro-
priate treatment of children less than five years of age is
particularly important in preventing mortality and curtailing
morbidity. The Roll Back Malaria (RBM) Partnership has set
a target of 80% receiving appropriate treatment within 24
hours by 2010,37 but in 2003 only 42% received any antima-
larial drugs.38 It is increasingly recognized that medicine sell-
ers can have a role in scaling-up coverage of appropriate ma-
laria treatment, and their role could potentially extend to the
provision of ACTs.20,39,40
* Address correspondence to Catherine Goodman, KEMRI/
Wellcome Trust Research Programme, P.O. Box 43640, Nairobi,
00100, Kenya. E-mail: catherine.goodman@lshtm.ac.uk
Am. J. Trop. Med. Hyg., 77(Suppl 6), 2007, pp. 203–218
Copyright © 2007 by The American Society of Tropical Medicine and Hygiene
203
This report draws together the literature on the character-
istics and operation of medicine sellers in sub-Saharan Africa,
and reviews all interventions designed to improve their ma-
laria-related practices. The scope and nature of the interven-
tions are described, and the evidence of their impact in terms
of provider and consumer knowledge and behavior, cost and
cost-effectiveness, and sustainability are assessed.
METHODS
Definition of medicine sellers. For the purposes of this re-
view, medicine sellers were defined to include all commercial
retailers supplying fever/malaria drugs, except formal phar-
macies that are required to be staffed by a qualified pharma-
cist. Medicine sellers are variously known as drug sellers,
chemical sellers, and patent medicine vendors (PMVs), and
operate in specialist drug shops as well as general shops,
kiosks, and market stalls, and as itinerant hawkers. Such out-
lets are not permitted to stock prescription-only medicines,
but in some cases are allowed to sell over-the-counter (OTC)
products, such as cough syrups, painkillers, and some antima-
larial drugs. No professional consultation is required for pur-
chase, and staff are not required to be fully qualified phar-
macists. We focused on these outlets because they are the
most accessible and widely used, although many similarities
can be recognized with the operation of some formal phar-
macies, which are not always staffed by appropriate person-
nel,41 and with some basic private clinics.42
Search strategy. We first identified papers on the practices
of medicine sellers in sub-Saharan Africa, including studies
focusing on antimalarial drugs and more general drug sales.
Second, we identified all studies of interventions to improve
the delivery of malaria-related treatment services involving
medicine sellers in sub-Saharan Africa. The intervention re-
view was based on a RBM commissioned report by Brieger,
Unwin, Greer, and Meek.43 Malaria-related was defined to
include fever and malaria because most malaria diagnoses in
the region are based on febrile symptoms alone.
Internet searches using PubMed formed the first level of
inquiry, using search terms related to the three inclusion cri-
teria: medicine sellers, sub-Saharan Africa, and malaria. Be-
cause most work in this area has been done relatively re-
cently, much is not yet formally published. Key terms were
therefore used in general search engines, and gray literature
libraries were searched. Personnel in various health and de-
velopment agencies operating in Africa were contacted to
identify additional studies. Finally, the team obtained contact
information about each intervention project and made direct
inquiries to fill gaps in project descriptions. Attempts were
made to identify interventions continent-wide, but it is pos-
sible that there was some degree of anglophone bias in the
search strategy.
RESULTS
Characteristics and operation of medicine sellers. A range
of studies have looked specifically at the retail supply of an-
timalarial drugs in sub-Saharan Africa,10,20,27,44–58 and others
have looked more broadly at the retail sector drug sup-
ply.15,18,19,24,25,59–69 The studies are roughly equally divided
between rural and urban/peri-urban areas, with several cov-
ering both settings. Methods consisted mainly of structured
questionnaires administered to sales staff, supplemented in
some cases by in-depth interviews, undercover care-seekers,
direct observation, outlet mapping, exit interviews, and
household surveys.
There is considerable variation in retailer type across set-
tings. In most areas, a limited range of drugs is sold by general
grocery stores and kiosks, alongside a range of household
goods such as soap powder, batteries, and cooking
oil.27,53,57,70 In addition, in some areas of east and west Africa,
a wider range of medicines is sold by small drug shops spe-
cializing in pharmaceuticals.19,49,53,64,65,71 In much of west Af-
rica, itinerant vendors are important retail suppliers,18,44,47,59
although they are much less common in east and southern
Africa. For example, in Ibarapa District in western Nigeria,
medicine peddlers on motorcycles were found to provide the
bulk of western health care to remote hamlets.59 In some
settings, the drug seller market is extremely informal, includ-
ing market traders with bowls of exposed tablets and capsules
among which customers pick and choose, and hawkers wan-
dering the streets,58,70 although most medicines are likely to
be sold through more formal outlets.
The legal status of retailers varies, with each country having
its own procedures and categories of licenses. Some operate
entirely within the law, others are legal entities but perform
some illegal activities, and others are completely illegal out-
lets. Because the legal boundaries for drug retailing vary
across countries, a legal activity in one country may be con-
sidered illicit elsewhere. In some west African settings, retail-
ers have formed trade associations, e.g., the Nigerian National
Association of Patent and Propriety Medicine Dealers,
founded in 1951,59 which requires prospective members to be
inspected and interviewed.72 Such associations have not been
documented in east or southern Africa, although medicine
sellers may link with associations such as the Private Dispens-
ers’ Association in Uganda, when they operate under the
license of a qualified private dispenser.
Of medicine seller clients, a high proportion are seeking
care for fever or malaria, with other common complaints be-
ing colds/flu, headaches and stomach aches, diarrhea, and
sexually transmitted infections (STIs).19 Of those with fever/
malaria, a small proportion are reported to have severe dis-
ease, for which greater use is made of formal health facilities,
or in some cases traditional healers.6,12,73–75 However in Tan-
zania, medicine seller clients reporting fever were as likely as
health facility clients to have parasitemia, indicating that the
provision of effective antimalarial drugs is important for both
groups.56
Similarities across drug retailers can be noted, particularly
in stocking patterns. Nearly all stock modern manufactured
medicines only, an exception being the Amayeza stores in
South Africa’s Eastern Cape Province, which also stock a
wide range of traditional remedies.62 Retailers tend to sell a
wide variety of painkillers/antipyretics and the first-line anti-
malarial drug, which at the time of most studies was chloro-
quine or sulfadoxine-pyrimethamine (SP). These drugs were
generally available under their generic (non-proprietary)
name and under a variety of brand names,10,19,49,53 with 30
different SP brands identified in rural Kenya.76 Other prod-
ucts regularly stocked include anthelminthics, antihistamines,
antiprotozoal drugs, and cough and stomach ache remedies.
Most drug stores stock prescription-only medicines illegally,
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such as antibiotics and tranquilizers, which are often kept
under the counter.15,18,19,54,59,60,63,64,68,77
Information on medicine seller sales volumes is available
from only two sources, both of which indicate that they can be
significant. In rural Tanzania, medicine sellers accounted for
39% of total antimalarial drug volumes provided in the com-
munity, mainly through specialist drug stores.20 General
stores stocking antimalarial drugs sold a mean of 74 equiva-
lent adult doses per year (worth $38) and drug stores 2,310
per year ($1,731).20 In Lagos, Nigeria more than $4,076 worth
of antimalarial drugs were sold in a week in 343 shops in three
neighborhoods.23
Medicine sellers often store and handle drugs in inappro-
priate ways, keeping them in conditions of excessive heat,
light, and moisture that may endanger their potency, and stor-
ing them in re-used, wrongly labeled containers.15,18,29,57 Poor
quality antimalarial drugs on the private market have been
identified through laboratory testing in Cameroon, Nigeria,
Tanzania, Kenya, and Uganda.78–85 For example, of samples
collected from illegitimate outlets in urban and rural areas of
Cameroon, 12% of anti-folates (including SP), 38% of chlo-
roquine, and 74% of quinine samples had either no active
ingredient, an insufficient active ingredient, the wrong ingre-
dient, or an unknown ingredient.30 This may reflect poor
manufacture, inadequate storage, and in some cases deliber-
ate counterfeiting. Packaging and labeling of products are
also highly inadequate. Labeling is often unclear, instructions
are rarely given in the local language, measuring devices are
not provided for syrups, and dosing information is often in-
adequate or in conflict with national treatment guidelines.57
Even those medicine sellers officially allowed to sell drugs are
usually permitted to sell pre-packaged products only, but this
regulation is frequently flouted; of antimalarial tablets dis-
pensed in rural Tanzania, packaged tablets made up only 22%
of tablet sales volumes from medicine sellers.20 Moreover,
where packaged medicines are stocked, they are sometimes
broken up to sell individual pills.18
In most encounters with their customers, medicine sellers
simply sell what the customer requests. Few sellers are pre-
sented with a prescription from a trained health professional,
nor do they request one prior to making a sale.15,19,46,54,59,60,65
However, some sellers give a considerable amount of advice
on drugs and doses.65,86 In Uganda, many customers asked
for such advice, and drug shop staff often made instant diag-
noses and drug recommendations, operating as storefront
clinics.19 Common information sources for shopkeepers are
the radio, their wholesalers, and the instructions provided by
manufacturers.20,46,50 However, medicine sellers rarely ask
customers questions about the illness65 and vary widely in the
amount, accuracy, and quality of information given on how to
take the medicines.26,29,63,77,87 Instructions are often un-
clear,29 and misinformation is often provided.87 Preventive
information is rarely shared with the customer.29,63 However,
poor quality treatment is not limited to the retail sector; the
performance of formal health facility workers is often also
poor, with frequent selection of inappropriate drugs and in-
correct dosages.88
Education levels vary across medicine sellers, but most
have little or no formal training in medicine or pharmacy.
Drug shop staff may be untrained, or trained as medical as-
sistants or nurses, perhaps with some experience in the formal
health sector.19,20,49,59 In some cases, government health per-
sonnel work in drug stores as well.19 Even where the official
owner or licensee has health-related qualifications, outlets are
often staffed by less qualified assistants.59,64,65,89 Staff in gen-
eral shops rarely have any training or relevant experience,
and in Uganda many were illiterate.19,20
Relatively little is known about the distribution chain to
medicine sellers beyond their immediate sources. Retailers
usually obtain drugs from general wholesalers or large retail
or wholesale pharmacies, although mobile distributors oper-
ate in some settings.52,53,64,76,90,91 In Nigeria, sales represen-
tatives from pharmacies and pharmaceutical companies were
the main source of drugs for medicine sellers in a peri-urban
area.64 Retailers may use formal as well as informal channels,
and some studies have reported significant quantities of
smuggled drugs in shops,18,47 including those labeled for ex-
clusive government use (Unwin A, unpublished data).
In Abia, Nigeria, low staff turnover rates were found
among medicine sellers, with more than half of shop owners
and/or attendants working in the same shop for at least 4
years, and almost a quarter for at least 10 years.92 In contrast,
in east Africa the retail market appeared to be highly dy-
namic, with a significant proportion of sellers entering and
exiting the business in any given year.20,93 For example in
rural Tanzania, during a one-year period 29% of general
stores stocking drugs had closed down, and an additional 7%
remained open but no longer stocked drugs; these reductions
were more than compensated for by new stockists.20 The most
commonly cited reason for closing down was erosion of capi-
tal. However, such high rates of closure appeared less com-
mon among drug stores and general wholesalers.
Determinants of medicine seller behavior. The determi-
nants of medicine seller behavior have received relatively
little attention compared with descriptive work on their char-
acteristics and operation. One would expect their behavior to
be influenced by a range of factors: their knowledge and clini-
cal skills, client expectations, profit margins, pharmaceutical
company promotions, and local regulation.41,94
Studies show that medicine seller knowledge of drugs and
doses is often poor. For example, among retailers in rural
Tanzania, knowledge of signs and symptoms of malaria was
adequate, but 90% did not know precise chloroquine doses
for children.50 In Nigeria, only 1 of 49 patent medicine vendor
owners knew the correct dose of chloroquine for a three-year-
old child.59 Inadequate medicine seller knowledge is likely to
be exacerbated by the recent introduction of ACT in sub-
Saharan Africa because these have new dosage regimens, and
more than one product may be available with different dos-
ages. For example, in Nigeria 95% of medicine sellers incor-
rectly considered artesunate monotherapy to be an ACT.72
Another important determinant of provider behavior is medi-
cine sellers’ beliefs about patients’ attitudes and preferences.
For example, even if they are aware that an oral therapy
would be appropriate, they may sell injectable formulations if
they know that patients believe injections to be more effec-
tive. However, careful interpretation of claims of such con-
sumer pressure is required because providers may choose to
blame consumers for their own profit-maximizing strategies.
One would also expect retailers behavior to be influenced
by cost structure, profit margins, and competition from other
providers, and to be more responsive to these financial incen-
tives than would be their public sector counterparts. In the
rural retail market in Tanzania, price competition for an-
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timalarial drugs was limited because there were relatively few
antimalarial drug retail stockers and the market was strongly
segmented geographically, meaning that people did not gen-
erally travel far to seek care.20 This limited competition was
associated with high retail markups, which were also docu-
mented in rural Kenya.76 However, in urban areas much
greater price competition between retailers would be ex-
pected. It should also be noted that medicine seller incentives
are unlikely to be purely financial; they may also include a
desire to serve the community, to be seen as a respectable,
trustworthy citizen, or to be viewed as professionally compe-
tent by their peers.
Last but not least, one would also expect regulation to
affect medicine seller operations. The scope of such regula-
tion generally concerns the availability, labeling, dispensing,
and marketing of drugs, the qualifications of staff, the loca-
tion and nature of the premises, and in some circumstances
the prices charged. However, retail regulation is notoriously
ineffective. For example, in Kano State, Nigeria, only 15% of
drug sellers were registered with the Federal Government.94
In Uganda, 60% of chloroquine purchases reported in a
household survey came from sources not authorized to pro-
vide antimalarial drugs.19 In Tanzania, 90% of drug stores
illegally stocked prescription only antimalarial drugs, most
stocked unregistered products, and all drug store serving staff
were underqualified.54
Strengthening regulatory control has posed great chal-
lenges because of the lack of enforcement capability.94,95 In a
peri-urban area of Nigeria, only 33% of PMVs reported an
inspection visit during the previous two years.64 In Dar es
Salaam, more than half of pharmacy owners rated the gov-
ernment’s effectiveness in regulating the pharmaceutical sec-
tor as low or very low, for example, citing the failure to pe-
nalize shops flouting regulations and the lack of regular in-
spections.96 This was argued to reflect inadequate staffing and
transport. In rural Tanzania, regulatory infringements were
argued to reflect a combination of infrequent regulatory in-
spections, a failure of regulatory authorities to implement
sanctions, and successful concealment of violations.54 In ad-
dition, there may be tacit permission of violations by local
regulatory staff, who see enforcement as unfeasible and/or
recognize that provision of prescription-only medicines in
shops meets a genuine need in communities without formal
pharmacies where government facilities frequently experi-
ence drug stockouts.54
Interventions involving medicine sellers. A total of 16 in-
terventions to improve malaria-related activities of medicine
sellers in sub-Saharan Africa were identified and are summa-
rized in Table 1. Five were based in Nigeria, four in Kenya,
two each in Uganda and Ghana, and one each in Tanzania,
Madagascar, and Zambia. It is notable that only one was
found outside anglophone Africa; this may have reflected a
greater likelihood of identifying English literature in the
search, or greater reluctance to engage with medicine sellers
on the part of francophone governments. The interventions
varied considerably in scope and scale. All involved a com-
bination of training, job aids, and demand generation/
consumer information, with some including pre-packaged
drugs. Franchise/accreditation networks were developed in
three cases. In terms of health problems addressed, nine fo-
cused specifically on malaria treatment, two included acute
respiratory infections (ARIs) and/or diarrhea as well, and five
had a more general primary health care orientation. All but
one intervention involved working with existing medicine
sellers, the exception being Child and Family Wellness
(CFW) shops™ in Kenya where new outlets were established.
In six interventions, medicine sellers were the primary focus,
and in an additional six they had a major role, complemented
with other strategies to improve medicine use. In the four
remaining projects, medicine sellers had only a partial role as
an adjunct to the main community health intervention. The
number of medicine sellers involved ranged from 12 to more
than 3,000. The earliest began in 1990, although all but three
were initiated in 2000 or later, demonstrating that widespread
interest in this area is a relatively recent phenomenon.
Four major intervention components were identified: 1)
training/capacity building, 2) demand generation, 3) quality
assurance, and 4) creating an enabling environment. Table 2
shows the number of interventions including each component
and the activities covered.
All projects had an element of training and capacity build-
ing, including workshops, peer or in-shop education, and job
aids. The three most common elements of training content
were drug use, communication, and referral. Other topics in-
cluded common health problems, safety, pharmacy law, man-
agement skills, and procedures unique to the intervention
(e.g., franchising procedures). Management skills included fi-
nance, record keeping, business ethics, and stock mainte-
nance. Six projects conducted in-shop or peer education vis-
its.52,97–99 For 10 interventions, it was stated that take-home
materials and job aids were provided to trainees.52,59,90,92,97–102
In one intervention, negotiation sessions were conducted, an
approach in which the public health objectives and the factors
influencing private practitioner behavior are taken into ac-
count in jointly devising what improvements to introduce.42
Demand generation was addressed in 12 interventions us-
ing 2 approaches. Ten projects included mass media or public
information components.52,90,98,99,101–106 For example, the
KidCare intervention to socially market pre-packaged anti-
malarial drugs in Nigeria involved TV, radio, mobile video
units, posters, billboards, leaflets, flyers, point of sale stickers,
danglers, promotional material, and special events, with mes-
sages focusing on product information, malaria, and its treat-
ment and prevention.99 Five projects trained community vol-
unteers to promote patronage of trained medicine sellers and
appropriate medicines.52,90,97,103,107 Demand was also stimu-
lated through subsidies on pre-packaged antimalarial drugs in
Madagascar108 and at the initial introduction of pre-packaged
drugs in Nigeria.
Quality assurance was addressed in 14 interventions in 5
main ways: 1) franchising or accreditation, 2) consumer ac-
countability, 3) engaging a medicine seller association, 4)
monitoring and supervision, and 5) pre-packaged drugs. Un-
der franchising/accreditation, trained outlets obtaining ac-
creditation or specific recognition received signs, posters, or
stickers that identified them as an accredited outlet. The net-
works were publicized through identifiable names, brands,
and logos. Franchising or accreditation was central to three
projects, CFWshops™ in Kenya, accredited drug dispensing
outlets (ADDOs) in Tanzania, and CAREshops in
Ghana.105,109,110 An element of franchising was also found in
the project promoting pre-packaged antimalarial drugs in
Abia, Nigeria, in that medicine sellers were provided with
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shop stickers, posters, and danglers that designated them as
trained providers of the RBM logo-branded pre-packaged
drugs.92
Three projects reported that some form of consumer ac-
countability was built into the design, including the use of
community-based organizations to identify, recruit, and moni-
tor medicine sellers.92,98,107 Four projects mentioned the use
of existing, or formation of new medicine seller associations,
to assist in establishing norms and supporting/ expanding
training.59,92,103,107 Monitoring and supervision post-training
was built into nine projects.42,52,98,100,101,103,105,106,109 Five
projects addressed drug quality and packaging: four specifi-
cally focused on promoting pre-packaged antimalarial
drugs,92,99,102,103 and the fifth focused on pooled procurement
that was used for CAREshop franchised sellers to obtain bulk
discounts and ensure drug quality.105
Seven programs addressed the enabling environment; five
addressed changes in drug pol ic ies and regula-
tions.72,99,104,105,111 The ADDO program linked accreditation
with enabling medicine sellers to sell both OTC drugs and
limited prescription drugs,104 and decentralized regulation of
accredited outlets from regional to ward level.112 In Nigeria,
the national food and drug agency approved new pre-
packaged drugs (Gilpin U, unpublished data), and later the
Society for Family Health (KidCare project) played an influ-
ential role in the rescheduling of ACTs as OTC medicines,
enabling them to be introduced into the antimalaria drug so-
cial marketing project.99 The projects associated with fran-
chising reported that credit facilities were available to help
medicine sellers improve their business.104,113,114
Formal evaluations were identified for 11 interventions and
are classified according to their study design in Table 1.
Evaluations were defined as those that documented changes
over time (pre-post–six evaluations), compared an interven-
tion area with a control area (controlled–one evaluation), or
compared changes over time in an intervention area with
changes over time in a control area (pre-post with control–4
evaluations), and documented impact in terms of knowledge,
behavior, or community drug use. Of the studies involving
baseline and follow-up data, the time between intervention
implementation and the follow-up survey ranged from zero
(immediate assessment of knowledge post-training59) to a
year or more.90,115
Table 1 also shows the key outcome measures used. None
of the projects attempted to assess the impact on malaria
morbidity or mortality, instead assuming that improved ac-
cess to appropriate knowledge and/or improved antimalarial
drug use would improve child survival. Of the potential out-
come measures, community drug use could be considered
most closely linked to health outcomes, but such measures
were used in only two evaluations. The impact on consumer
knowledge was documented by two studies, on provider
knowledge by five studies, and on provider behavior by two
studies.
Medicine seller knowledge. Pre-training and post-training
assessment of medicine seller knowledge was conducted
through testing in five interventions,52,59,92,101,115 with several
studies demonstrating improvements. For example, trained
PMVs in Igbo-Ora, Nigeria, had significantly higher scores in
a test on simple medicine use and appropriate practices for
malaria management (increase from 46% to 70%),59 and in
Kisii, Kenya, the percentage of sellers who knew the correct
chloroquine dose for children less than five years of age in-
creased from 0% to 59%.101 In Ghana, there was an increase
in the proportion of franchised CAREshops scoring more
than 60% on a test on managing simple ailments from 35% to
82%.115
Medicine seller performance. Seller performance was as-
sessed for five interventions.42,52,90,104,106 Because medicine
sellers have incentives to put on their best behavior before an
open observer, or present a wishful self-image under ques-
tioning,116 all studies evaluated provider behavior through
mystery shoppers/simulated clients.
All interventions reported improvements in medicine seller
performance. For example, in Bungoma, Kenya, the propor-
tion of sellers stocking recommended antimalarial drugs was
62% in outlets that had received job aids compared with 23%
in controls.52 In Tanzania, the proportion of drug stores
stocking unregistered medicines was 2% in accredited stores
compared with 10% in controls.112 The proportion giving ap-
propriate drugs for uncomplicated malaria increased from 2%
to 73% after negotiation sessions in Luwero, Uganda.42 The
proportion of sellers recommending or giving a correct anti-
malarial drug dose also showed substantial improvements,
increasing from 9% to 53% after training and introduction of
pre-packed antimalarial drugs in Abia, Nigeria,92 and from
0% to 50% after negotiation sessions in Uganda.42
There were also improvements in the provision of advice to
consumers. The Ugandan negotiation sessions increased the
proportion of sellers who explained how to give the medicine
from 8% to 49%.42 In Abia, Nigeria, the proportion of sellers
who asked whether the customer understood the information
provided increased from 35% to 54% for uncomplicated ma-
laria, but only from 29% to 33% for complicated malaria.106
TABLE 2.
Intervention components
Intervention
component
Training and
capacity building Demand generation Quality assurance Creating an enabling environment
Activities Workshops, courses, and
orientations
Peer and in-shop
education
Supportive instructional
materials, job aids
Mass media and
information
Community
promoters and
mobilization
Subsidies
Franchising and accrediting
Community accountability
Medicine seller association
oversight
Monitoring and supervision
Prepackaging and drug quality
Drug policy and regulation
Credit facilities
No. of interventions
including this
component (n  16)
16 12 14 7
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Not all indicators showed universally positive changes. For
example, performance on referral practices was disappointing
in Abia, Nigeria, where there were decreases in both the pro-
portion explaining danger signs to caregivers and the propor-
tion referring cases of convulsions.92 In Kilifi, Kenya, the pro-
portion asking about danger signs was higher in intervention
shops compared with controls (26% versus 0%) but still re-
mained unacceptably low.90 In Tanzania, there was concern
that referral rates for uncomplicated malaria may have in-
creased too much, with 52% of accredited drug stores refer-
ring clients rather than providing antimalarial drugs them-
selves compared with 21% in controls, although it had been
anticipated that most cases could be appropriately managed
at medicine seller level.112 Experience with preventive prac-
tices was also mixed, with three interventions showing little or
no improvement in the proportion of sellers advising caregiv-
ers about prevention.42,90,92
In some cases, there was a disappointing lack of behavior
change despite significant improvements in seller knowledge
in the relevant area. For example, in Abia, Nigeria, there was
a significant improvement in the proportion of PMVs able to
name signs of severe illness, but a decrease in the proportion
explaining these signs to caregivers and referring severe
cases.92 This may have reflected a concern that such actions
would decrease the medicine sellers’ sales.
Caregiver knowledge and choice of provider. Interventions
that included community education also demonstrated an in-
crease in caregiver knowledge.97,100 For example, after train-
ing and community mobilization in Zambia, caretakers were
32% and 51% more likely to identify simple and severe ma-
laria, respectively.97 There is no evidence that working with
shopkeepers leads to an increase in the use of shops. For
example, in Kilifi, Kenya, shopkeeper training and commu-
nity information activities had no significant impact on the
proportion of fevers treated through shops.90 Interestingly,
two interventions that included other groups in the training,
such as VHWs and clinic staff, actually recorded a decrease in
medicine seller use. In southern Nigeria, medicine sellers re-
mained the most common source of treatment but there was
a small increase in the use of VHWs.103 In Ssembabule,
Uganda, there was a large decrease in medicine seller use
from 47% to 4%, and the use of health units increased from
32% to 71%.100
Rates of appropriate treatment. Only two studies assessed
the impact on community drug use, with both using large-
scale household surveys. In rural Nigeria, promotion of pre-
packaged antimalarial drugs through community distributors
including medicine sellers led to an increase in antimalarial
drug use for reported fever from 38% to 50%, which could be
attributed directly to the sale of project drugs.103 In Kilifi,
Kenya, training general shopkeepers, accompanied by com-
munity mobilization and monitoring/supervision activities,
was shown to lead to an increase in the proportion of shop-
treated childhood fevers receiving an adequate amount of a
recommended antimalarial drug from 2% to 15% after train-
ing on chloroquine and to 30% after subsequent training on
SP.90
Sustainability. The evidence of sustained improvement in
medicine seller performance and lasting impact on caregiver
behavior is limited, especially once outside involvement from
researchers and/or donors has ceased. However, in Kilifi
Kenya, persistent improvements in appropriate treatment
were demonstrated over several years.90 Because the primary
work of the medicine seller is to run a business, one aspect of
potential sustainability that can be relatively easily assessed is
whether sellers perceive commercial benefits from participa-
tion, such as increased prestige and/or higher profits. In gen-
eral, sellers were highly enthusiastic, and in several cases ex-
pressed a desire for further training because they believed
that the process either increased their turnover or gave them
increased credibility within the community.59,90,92,100,107
However, high attrition rates among medicine sellers posed a
challenge for sustainability in southern Nigeria, where 53% of
sellers dropped out,103 and in Ibgo-Ora, Nigeria, sustaining
knowledge gains when apprentices graduated was problem-
atic.59 In Kilifi, Kenya, 30% of trained shopkeepers had
stopped selling drugs in the first year of the intervention,
although this was reduced to 5% in subsequent years by se-
lection of more stable retailers.93
Cost. Another key factor influencing sustainability is the
intervention cost. Cost data were available from six interven-
tions,42,52,92,93,101,113 although comparison between studies is
hampered by variation in the scope of costs included.
The evaluation of general shopkeeper training in Kilifi,
Kenya, provided the most comprehensive cost data, and was
the only study to estimate the cost-effectiveness of the inter-
vention in terms of treatment outcomes.93 During the early
implementation phase, the full economic cost per year to the
provider (including annualized development and set-up year
costs) was $87.82 per trained shop, $0.46 per capita, and $4.00
per additional febrile episode appropriately treated (year
2000 US$) . It was estimated that if the project were imple-
mented at scale and run entirely by Ministry of Health staff,
the costs would decrease to $18.41 per trained shop, $0.10 per
capita, and $0.84 per additional febrile episode appropriately
treated, with the latter figure varying between $0.37 and $1.36
in the sensitivity analysis. The investigators used a simple
model to estimate the cost per death and disability-adjusted
life year (DALY) averted, which predicted a cost per death
averted of $505.42 for the early implementation phase and
$105.92 for operation at scale, and a cost per DALY averted
of $18.38 and $3.85, respectively, both of which would be
considered highly cost-effective in relation to commonly used
benchmarks.117
Other training interventions provided a range for the cost
per seller trained of $8–23. Training retailers and providing
information, education, and communication materials in
Kisii, Kenya, was estimated to cost $8 per trainee (2002
US$).101 Another Kenyan intervention in Bungoma found
that providing training and materials to wholesalers cost $9–
11 per retailer reached (2000 US$), excluding the time of
district health personnel and outside technical advisors.52 In
Abia, Nigeria, where training on the use of new pre-packaged
antimalarial drugs was offered to medicine sellers as part of a
social marketing campaign, $22.64 was spent directly on train-
ing and behavior change materials for each seller recruited
(excluding staff time, travel, and program development costs)
(2003 US$).92 Finally, negotiation sessions to improve key
child care practices in Luwero, Uganda, cost $21 per provider,
excluding the cost of community information (2003 US$).42
The costs for establishing new outlets under the CFW fran-
chise network in Kenya were understandably much higher,
with an average start up cost per shop of US$5,000 over the
first three years.113 No cost data were available for the fran-
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chise/accreditation networks in Tanzania and Ghana, al-
though the high costs of maintaining and scaling-up the net-
works have been noted as a major cause of concern by the
projects.115
DISCUSSION
This review has demonstrated that there are few reported
interventions that have sought to work with medicine sellers
to improve malaria treatment in Africa. This is in sharp con-
trast to the numerous published articles that not only docu-
ment community use of medicine sellers, but also subse-
quently recommend that intervention should follow.
Moreover, evaluation data from these interventions are
relatively weak; only 11 interventions had been formally
evaluated, and peer-reviewed publications were available for
only 5. In most cases, evaluation measures were limited to
intermediate outcomes (such as provider knowledge and be-
havior), rather than those more closely linked to health out-
comes (such as community drug use). Few studies provided
comprehensive cost or cost-effectiveness data. Limitations in
study design were also noted. No evaluations involved ran-
domization of outlets/areas to intervention and control
groups, which probably reflects the complexity of undertak-
ing a randomized controlled trial while maintaining realistic
program implementation and working with pilot projects.
Most evaluations had no control group, relying instead on pre
and post data, which may be subject to numerous confound-
ing factors. Moreover, because the post-intervention assess-
ments were often undertaken only three or four months after
implementation, long-term impact is difficult to pre-
dict.42,92,101
Despite these limitations, some tentative conclusions are
possible. Two key findings are that medicine sellers are inter-
ested and willing to participate, and that interventions involv-
ing them can increase the frequency of appropriate treatment
of malaria and other childhood illnesses. All interventions
reported improvements in medicine seller knowledge and/or
performance. The proportion of retailers who stocked ap-
proved drugs, dispensed age-appropriate dosages, and ad-
vised caregivers about appropriate management were all
shown to improve. The one study that used community sur-
veys to assess the impact on rates of appropriate treatment
showed strongly positive results. However, even where major
improvements were documented, a significant proportion of
febrile cases were still inappropriately treated. Post interven-
tion, for example, 60% of shop treated fevers still did not
receive an adequate dose of a recommended antimalarial
drug in Kilifi, Kenya,90 and 50% of private practitioners failed
to give the correct antimalarial dose in Luwero, Uganda.42
Because medicine sellers were already active in many com-
munities, interventions did not in general require investment
of external funds to establish outlets (an exception was the
CFW network). The resources required to implement the
programs were still significant, with costs ranging from $10 to
$30 per outlet trained when operating at a reasonable scale.
However, if significant changes in treatment outcomes are
achieved, this may still represent a highly cost-effective use of
resources.
These conclusions are supported by evidence from inter-
ventions focusing on other health issues, such as diarrheal
diseases, ARI, STIs, and contraceptives, and those working
with pharmacies rather than medicine sellers, both within
and outside Africa.118–137 Reproductive health and STI inter-
ventions have changed the knowledge and sales behavior of
medicine sellers, reducing inappropriate use of antibiotics
and encouraging use of syndromic management guide-
lines.124–126,128,135–137 For example, in Kampala, Uganda, so-
cial marketing of pre-packed STI treatment (Clear Seven) led
to significant improvements in cure rates, compliance, and
condom use.129 Face-to-face educational outreach on diar-
rhea treatment in Kenyan pharmacies led to a significant in-
crease in the knowledge of counter attendants, an increase in
sales of oral rehydration salts, and a decrease in antidiarrheal
sales.118 However, a similar intervention to improve ARI
treatment in pharmacies and drug shops in Kampala, Uganda
did not improve dispensing practices, with persistent provi-
sion of antibiotics and little advice provided.119 This was at-
tributed to client demand for particular drugs, competition
among drug outlets, and the inability of most clients to afford
the recommended treatments.
There is insufficient evidence to conclude that any one ap-
proach to working with medicine sellers is superior in improv-
ing malaria treatment. Similarly, it is not possible to isolate
the additional benefits of each component in these generally
multi-faceted interventions. However, a number of key fea-
tures of successful interventions can be suggested, based pri-
marily on the views of their implementers and evaluators.
First, the planning process should begin with a comprehen-
sive situation analysis, including the legal and market envi-
ronment. For example, the regulatory framework in which
medicine sellers operate, the channels through which they
obtain drugs, and nature of competition between providers
should all be understood. It is also important to document
rates of closures and new start-ups because interventions that
focus resources on relatively permanent sellers are likely to
be more sustainable and cost-effective. Guidance on under-
taking a situation analysis for home care of malaria including
medicine sellers has been developed.138
Second, interventions with the widest buy-in were generally
more successful. The involvement of medicine sellers, public
health officials, and community representatives in curriculum
development, training, and supervision was believed to con-
tribute to acceptability and effectiveness, and political sup-
port from central and local officials was essential. The two
interventions that appeared to have worked most closely with
national drug regulatory authorities and other Ministry of
Health partners achieved the most significant policy changes.
As a result of the Ugandan negotiation session intervention in
Luwero, a national strategy for involving private health prac-
titioners in child survival was developed.111 In Tanzania, new
legislation was drafted creating a separate class of accredited
medicine sellers.104
Third, effective interventions require a combination of ap-
proaches, which should go beyond short-term shopkeeper
training. Because client knowledge is a strong determinant of
the outcome when drugs are bought from a retailer, concur-
rent community information programs are important. Pre-
packaged medicines also facilitate the provision of correct
medicines and dosages.
Finally, it should not be assumed that knowledge assessed
at the end of a period of training will be fully transferred into
practice once the trainee returns to his or her place of work.
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This may be addressed to some degree through ongoing re-
fresher training, continued monitoring of performance, and
supervision of trained sellers. However, where sellers lack
financial incentives to behave as they have been trained, such
problems are likely to prove persistent.
In deciding on the appropriate scope for an intervention, it
is useful to categorize interventions as targeted at either be-
havior change or role change. Behavior change interventions
focus on improved sales practices, such as selling an effective
antimalarial drug, not selling antibiotics, distributing pre-
packaged drugs, and asking appropriate questions. Role
change interventions train medicine sellers to be active health
care providers, as shown in the various franchising studies,
and may require enabling legislation to legitimize their ex-
panded role. Key components for behavior and role change
interventions are proposed in Table 3. Those focused on be-
havior change can provide short-term and relatively rapid
responses through brief, highly focused training. In contrast,
role change interventions involve more extensive engagement
with the health system, and more fundamental changes to the
sellers’ organization and management of their businesses.
These may lead to broader benefits in the long-term, but are
likely to have greater cost and capacity requirements.
In certain areas evidence is limited. No studies attempted to
evaluate the distribution of benefits across socioeconomic
groups. It is therefore not clear to what degree these inter-
ventions reach the poorest groups within their target areas,
although there is evidence that they are effective in generally
poor communities.59,90,104
The evidence is limited of sustained impact and capacity to
operate at a nationwide scale. Several approaches are in the
process of scaling up: 33 Kenyan districts have successfully
applied for Global Fund finance to adopt the Kilifi model of
shopkeeper training (Marsh V, unpublished data), CARE-
shops operate in 20 districts in Ghana, and the Tanzanian
accredited drug store model has expanded to cover approxi-
mately 400 shops (Briggs J, unpublished data). Social market-
ing of prepackaged antimalarial drugs already operates na-
tionwide in Madagascar, and is supported in 19 states in Ni-
geria (Chavasse D, unpublished data). However, major
logistical and financial challenges in maintaining large net-
works of outlets with trained personnel have been noted, such
as the capacity to provide refresher training, supervision and
regulation, and the high cost of training courses.105,112
In some settings the sheer number of medicine sellers and
the high turnover of outlets and staff may render face-to-face
training of each one infeasible on a national scale. One may
question whether the significant financial resources and long-
term supervision required to maintain a comprehensive train-
ing program or accreditation network are available in coun-
tries that currently struggle to provide regular supervision and
commodities to their own primary care facilities.57 However,
several projects have demonstrated the potential to outsource
these activities to non-governmental organizations and com-
mercial companies.105,110,139
Despite the success stories reported above, enthusiasm for
medicine seller interventions is not universally shared. In
many countries, calls for a more active role for retailers have
met with resistance from at least some government health
personnel, who favor stricter enforcement of pharmaceutical
laws or outright banning of medicine sellers.61,140 Several
sources of objection can be identified: that public-private col-
laboration with providers who routinely infringe current regu-
lations is inappropriate; that such interventions confer legiti-
macy on sellers with minimal training who may then be per-
ceived locally as health professionals; and that such
interventions reduce health facility use. However, there is no
evidence of large increases in medicine seller use after inter-
ventions; in some cases use actually decreased. Moreover,
standards of treatment are also often poor in formal health
facilities,88 and in some settings the quality of facility care
obtained is no better than that provided by medicine sell-
ers.20,26 Although poor facility performance clearly needs to
be addressed, discouraging medicine seller use may not im-
prove the quality of care received overall.
There is also concern that interventions that facilitate the
sale of previously prescription-only drugs by medicine sellers
may lead to indiscriminate use, increasing the risk of adverse
events and the development of drug resistance. These issues
have been raised in the context of the on-going introduction
of ACT in Africa. There are already plans to introduce ACT
through medicine seller interventions in Nigeria through the
KidCare social marketing program and in Tanzania through
ADDOs.72,141 Some argue that although it was appropriate to
deliver the old monotherapy regimens such as chloroquine
and SP through medicine sellers and other community-based
delivery systems, this would be inappropriate for ACTs be-
cause of the greater complexity of the dosing schedule, the
need for large subsidies to ensure affordability, the necessity
of prioritizing scarce ACT supplies, and the potential devel-
opment of resistance to these valuable and effective medi-
cines.142 Moreover, provision of highly effective ACTs at
health facilities may lead to a decrease in shop use for febrile
illness, as observed in Rufiji District in Tanzania (IMPACT-
TZ collaboration, unpublished data), reducing the need for
medicine seller programs. However, many of the perceived
advantages of retailers highlighted in the introduction will
persist, particularly their accessibility and importance as an
alternative drug source when public facilities stock out. It is
therefore likely that significant medicine seller use will con-
tinue in most settings, and it is questionable whether the
RBM target of 80% coverage of appropriate malaria treat-
ment in children less than five years of age can be achieved
TABLE 3
Key components for behavior change and role change interventions
Behavior change: relatively rapid
but limited change in
case management practices
Role change: longer-term change in
medicine seller roles to enhance health
systems
Medicine seller inventory
Medicine seller involvement,
e.g., through association
Training of trainers: health
workers, medicine sellers, or
others
Short training: workshops,
seminars
National treatment guidelines
Pre-packaged drugs in
age-specific packets
Supportive behavior change
materials in the form of job
aids, hand-outs for customers
Follow-up supervision
Standards of practice
Recruitment criteria
Franchising procedures
Training of trainers: health
workers, medicine sellers, or
others
Detailed training courses
Standard treatment protocols
Record keeping and
accountability systems
Branding, logos, and
identification
Credit facilities
Central drug stocks of quality
products at reasonable prices
Follow-up supervision
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without provision of antimalarial drugs outside facilities,
through either medicine sellers or community volunteers.40
Moreover, failure to promote ACTs through medicine sellers
may lead to widespread use of artemisinin monotherapies.72
These debates can only be addressed effectively through
empirical research to further evaluate medicine seller pro-
grams. There is a need to expand the geographic coverage of
existing studies to cover a wider range of locations and to
capture potential variations in effectiveness and cost-
effectiveness across epidemiologic and health system settings,
and with the different types of medicine sellers found across
Africa. The relative merits of conducting malaria-focused in-
terventions versus those covering a number of key primary
health care issues should be explored. Evaluations of inter-
ventions at scale should be conducted to assess the potential
sustainability of such programs and their potential to operate
nationwide. Such evaluations should include a wider range of
evaluation outcomes than those found in most studies to date,
encompassing indicators related directly to health outcomes
(e.g., proportion of children appropriately treated), interven-
tion costs, and cost-effectiveness, and the distribution of in-
tervention benefits by socioeconomic groups. In addition to
the use of standard public health approaches to evaluation,
such studies would benefit from the insights of both anthro-
pology and economics in exploring and explaining the behav-
ior of both medicine sellers and patients/caregivers.
CONCLUSIONS
Medicine sellers offer a service to patients that is widely
used for the treatment of fever and malaria in most of Africa.
Their popularity alone does not justify their use, but indicates
the importance of ensuring that they have the capacity to
provide safe and appropriate medicines in correct amounts in
the communities they serve.
Despite the limited number of evaluations conducted, there
is credible evidence that well-planned and implemented in-
terventions can improve quality of service. Experience from
the 16 malaria-related medicine seller interventions identified
in sub-Saharan Africa indicated that where medicine sellers
were taught about approved drugs, had the opportunity to
stock such drugs, and saw the benefits of providing guidance
on dosing, the proportion of clients that received the correct
dose of an effective drug could be substantially increased.
This provides a strong rationale for further exploring the
largely untapped potential of medicine seller interventions to
contribute to the achievement of the RBM targets.
In view of the limited evidence base and on-going intro-
duction of ACTs, there is an urgent need for further opera-
tional or intervention research to adapt these interventions to
the ACT era, and provide more comprehensive evaluations of
their impact, value for money, sustainability, and potential to
scale up to a national level.
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